368
Views
16
CrossRef citations to date
0
Altmetric
Original Research

Adherence to Buprenorphine Treatment Guidelines in a Medicaid Program

, MD, , PhD, , PhD, , MS & , MS
Pages 174-182 | Received 09 Jul 2014, Accepted 03 Nov 2014, Published online: 16 Jun 2015

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (3)

Rachel K. Landis, Jonathan S. Levin, Brendan Saloner, Adam J. Gordon, Andrew W. Dick, Tisamarie B. Sherry, Douglas L. Leslie, Mark Sorbero & Bradley D. Stein. (2022) Sociodemographic differences in quality of treatment to Medicaid enrollees receiving buprenorphine. Substance Abuse 43:1, pages 1057-1071.
Read now
Adam J. Gordon & Jennifer A. Jenkins. (2015) The Time Is Now: The Role of Pharmacotherapies in Expanding Treatment for Opioid Use Disorder. Substance Abuse 36:2, pages 127-128.
Read now

Articles from other publishers (13)

Alex K. Gertner, Hannah Margaret Clare, Byron J. Powell, Allison R. Gilbert, Hendree E. Jones, Pam Silberman, Christopher M. Shea & Marisa Elena Domino. (2022) A mixed methods study of provider factors in buprenorphine treatment retention. International Journal of Drug Policy 105, pages 103715.
Crossref
William J. Parish, Tami L. Mark, Gary A. Zarkin & Ellen Weber. (2021) The association of Medicare Part D prior authorization for buprenorphine–naloxone with adherence to opioid use disorder treatment guidelines in the United States. Addiction 117:1, pages 141-150.
Crossref
S.M. Hesam Hoseiny Morasa, Mohammad Haghighi, Sara Ataei & Maryam Rangchian. (2021) An Investigation on the Guideline Adherence in Opioid Addiction Treatment and the Causes of Nonadherences. Addictive Disorders & Their Treatment 20:4, pages 360-370.
Crossref
Tyler Varisco, Chan Shen & Douglas Thornton. (2020) Chronic prescription opioid use predicts stabilization on buprenorphine for the treatment of opioid use disorder. Journal of Substance Abuse Treatment 117, pages 108073.
Crossref
Tami L. Mark, Jesse M. Hinde, Gary A. Zarkin, William Parish & Marianne Kluckman. (2020) Adherence to buprenorphine treatment guidelines among individuals with an opioid use disorder who have private insurance. Journal of Substance Abuse Treatment 116, pages 108062.
Crossref
Alex K. GertnerAllison G. RobertsonByron J. PowellHendree JonesPam SilbermanMarisa Elena Domino. (2020) Primary Care Providers And Specialists Deliver Comparable Buprenorphine Treatment Quality. Health Affairs 39:8, pages 1395-1404.
Crossref
Paul M. Griffin. (2020) Engineering Approaches for Addressing Opioid Use Disorder in the Community. Annual Review of Biomedical Engineering 22:1, pages 207-229.
Crossref
Rosanna Smart, Courtney A. Kase, Erin A. Taylor, Susan Lumsden, Scott R. Smith & Bradley D. Stein. (2020) Strengths and weaknesses of existing data sources to support research to address the opioids crisis. Preventive Medicine Reports 17, pages 101015.
Crossref
Lydia Anne M. Bartholow & Justine Pope. (2018) Use of Buprenorphine to Treat Opioid Use Disorder. Journal of Psychosocial Nursing and Mental Health Services 56:11, pages 9-12.
Crossref
Ajay Manhapra, Ismene Petrakis & Robert Rosenheck. (2017) Three-year retention in buprenorphine treatment for opioid use disorder nationally in the Veterans Health Administration. The American Journal on Addictions 26:6, pages 572-580.
Crossref
Katherine E. Watkins, Susan M. Paddock, Teresa J. Hudson, Songthip Ounpraseuth, Amy M. Schrader, Kimberly A. Hepner & Bradley D. Stein. (2017) Association between process measures and mortality in individuals with opioid use disorders. Drug and Alcohol Dependence 177, pages 307-314.
Crossref
Adam J. Gordon, Wei-Hsuan Lo-Ciganic, Gerald Cochran, Walid F. Gellad, Terri Cathers, David Kelley & Julie M. Donohue. (2015) Patterns and Quality of Buprenorphine Opioid Agonist Treatment in a Large Medicaid Program. Journal of Addiction Medicine 9:6, pages 470-477.
Crossref
Bradley D. Stein, Adam J. Gordon & Andrew W. Dick. (2015) Buprenorphine Waivers: The Authors Reply. Health Affairs 34:8, pages 1428-1428.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.